Protalix Biotherapeutics, Inc. Signs $280 Million Brazilian Gaucher Deal

Published: Jun 19, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Shares of Protalix BioTherapeutics Inc. jumped in premarket trading Wednesday after the drug developer announced a deal that requires the Brazilian government to buy at least $280 million of the company's Gaucher disease treatment. The Israeli company said an arm of the Brazilian Ministry of Health has committed to buying at least $40 million of the drug annually during the seven-year agreement for Uplyso, which is marketed as Elelyso in the United States and Israel. During the agreement, Protalix will transfer the technology needed for the Brazilian government to build at its own expense a factory to make a sustainable supply of Uplyso. Protalix doesn't have to complete the final stage of its technology transfer until the government has made at least $280 million in Uplyso purchases.

Help employers find you! Check out all the jobs and post your resume.

Back to news